{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=NantCell%2C+Inc.",
    "query": {
      "sponsor": "NantCell, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=NantCell%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:28:22.638Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00813605",
      "title": "QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "FOLFIRI",
          "type": "OTHER"
        },
        {
          "name": "AMG 655",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AMG 479",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2009-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 28,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813605"
    },
    {
      "nct_id": "NCT00630552",
      "title": "QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Metastatic Pancreatic Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AMG 479",
          "type": "DRUG"
        },
        {
          "name": "AMG 655",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2007-06",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 44,
      "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 37 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630552"
    },
    {
      "nct_id": "NCT01147965",
      "title": "QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Lung Cancer",
        "Breast Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ad5 CEA Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-07-16",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Spokane, Washington",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147965"
    },
    {
      "nct_id": "NCT01856920",
      "title": "QUILT-3.006 for Recurrent Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Cancer (MTC)"
      ],
      "interventions": [
        {
          "name": "GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 35,
      "start_date": "2013-03-26",
      "completion_date": "2018-05-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01856920"
    },
    {
      "nct_id": "NCT01708161",
      "title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA Mutated Advanced Solid Tumors",
        "PIK3CA Amplified Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BYL719",
          "type": "DRUG"
        },
        {
          "name": "AMG 479",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2012-11-27",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-09-13",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01708161"
    },
    {
      "nct_id": "NCT02383498",
      "title": "QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chordoma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "GI-6301 Vaccine (Yeast- Brachyury)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "wGT3X-BT Actigraph",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-05-01",
      "completion_date": "2019-09-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383498"
    },
    {
      "nct_id": "NCT03127098",
      "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Colon Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Lung Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-06-26",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127098"
    },
    {
      "nct_id": "NCT01061788",
      "title": "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors, Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 479, Everolimus, Panitumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Clarke",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-04",
      "completion_date": "2018-12-19",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01061788"
    },
    {
      "nct_id": "NCT00807612",
      "title": "QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-01",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 25,
      "location_summary": "Fayetteville, Arkansas • Fort Wayne, Indiana • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807612"
    },
    {
      "nct_id": "NCT00626106",
      "title": "QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Tumors",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 156,
      "start_date": "2008-03-27",
      "completion_date": "2011-09-23",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-30T04:28:22.638Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00626106"
    }
  ]
}